Tesamorelin is a synthetic polypeptide that acts on growth hormone-producing cells in the pituitary gland and is usually metabolized locally by receptor-bearing cells. As a polypeptide, tesamorelin is unlikely to have direct cytotoxicity. Allergic responses to its administration did not elicit hepatic or systemic hypersensitivity responses.
The recommended dose is 2 mg per day given by subcutaneous injection. Side effects are not common but may include injection site reactions, itching, arthralgia, myalgia, and peripheral edema. Tesamorelin increases IGF-1 levels and monitoring for elevations during treatment is recommended. Potential and rare adverse events include stimulation of malignant tumor growth, glucose intolerance, diabetes, and hypersensitivity reactions.